Atomoxetine (Strattera) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children 6 years of age and older, in adolescents and in adults as part of a comprehensive treatment program. Treatment must be initiated by a specialist in the treatment of ADHD, such as a pediatrician, child/adolescent psychiatrist, or psychiatrist.

Place of Origin

Philippines

Directions

Atomoxetine (Strattera) can be administered as a single daily dose in the morning. Patients who do not achieve a satisfactory clinical response (tolerability [e.g. nausea or somnolence] or efficacy) when taking Atomoxetine (Strattera) as a single daily dose might benefit from taking it as twice daily evenly divided doses in the morning and late afternoon or early evening.

Ingredients

Atomoxetine hydrochloride

Warnings

Hypersensitivity to the active substance or to any of the excipients listed in Description. Atomoxetine should not be used in combination with monoamine oxidase inhibitors (MAOI). Atomoxetine should not be used within a minimum of 2 weeks after discontinuing therapy with MAOI. Treatment with MAOI should not be initiated within 2 weeks after discontinuing atomoxetine. Atomoxetine should not be used in patients with narrow angle glaucoma